Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survival
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.1007/s12282-020-01159-z http://hdl.handle.net/11449/206525 |
Resumo: | Background: Non-metastatic locally advanced breast carcinoma (LABC) treatment involves neoadjuvant chemotherapy (NCT). We evaluated the association of clinical–pathological data and immunoexpression of hormone receptors, HER2 and Ki67, and new biomarkers, RPL37A, MTSS1 and HTRA1, with pathological complete response (PCR) or tumour resistance (stable disease or disease progression), disease-free survival (DFS) and cancer-specific survival (CSS). Methods: This is a retrospective study of 333 patients with LABC who underwent NCT. Expression of MTSS1, RPL37A and HTRA1/PRSS11 was evaluated by immunohistochemistry in TMA slides. Cutoff values were established for low and high tumour expression. ROC plotter evaluated response to NCT. Chi-square test for factors related to PCR, and Kaplan–Meier test and Cox model for factors related to DFS and CSS were prformed. Results: The mean follow-up was 70.0 months and PCR rate was 15.6%. At 120 months, DFS rate was 32.5% and CSS rate was 67.1%. In multivariate analysis, there was an association between: (1) necrosis presence, intense inflammatory infiltrate, ER absence, HER2 molecular subtype and high RPL3A expression with increased odds of PCR; (2) lymph node involvement (LNI), high Ki67, low RPL37A and high HTRA1 expression with increased risk for NCT non-response; (3) LNI, high proliferation, necrosis absence, low RPL37A and high HTRA1 expression with increased recurrence risk; (4) advanced LNI, ER negative tumours, high HTRA1, low RPL37A expression and desmoplasia presence with higher risk of cancer death. Conclusion: RPL37A is a potential biomarker for response to NCT and for prognosis. Additional studies evaluating HTRA1 and MTSS1 prognostic value are needed. |
id |
UNSP_1c3adaaa54f1204f26a3e46fdcfb0f43 |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/206525 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survivalBiomarkers, tumorBreast neoplasmsNeoadjuvant therapyPathologic complete responseSurvival analysisBackground: Non-metastatic locally advanced breast carcinoma (LABC) treatment involves neoadjuvant chemotherapy (NCT). We evaluated the association of clinical–pathological data and immunoexpression of hormone receptors, HER2 and Ki67, and new biomarkers, RPL37A, MTSS1 and HTRA1, with pathological complete response (PCR) or tumour resistance (stable disease or disease progression), disease-free survival (DFS) and cancer-specific survival (CSS). Methods: This is a retrospective study of 333 patients with LABC who underwent NCT. Expression of MTSS1, RPL37A and HTRA1/PRSS11 was evaluated by immunohistochemistry in TMA slides. Cutoff values were established for low and high tumour expression. ROC plotter evaluated response to NCT. Chi-square test for factors related to PCR, and Kaplan–Meier test and Cox model for factors related to DFS and CSS were prformed. Results: The mean follow-up was 70.0 months and PCR rate was 15.6%. At 120 months, DFS rate was 32.5% and CSS rate was 67.1%. In multivariate analysis, there was an association between: (1) necrosis presence, intense inflammatory infiltrate, ER absence, HER2 molecular subtype and high RPL3A expression with increased odds of PCR; (2) lymph node involvement (LNI), high Ki67, low RPL37A and high HTRA1 expression with increased risk for NCT non-response; (3) LNI, high proliferation, necrosis absence, low RPL37A and high HTRA1 expression with increased recurrence risk; (4) advanced LNI, ER negative tumours, high HTRA1, low RPL37A expression and desmoplasia presence with higher risk of cancer death. Conclusion: RPL37A is a potential biomarker for response to NCT and for prognosis. Additional studies evaluating HTRA1 and MTSS1 prognostic value are needed.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Programa de Pós-Graduação em Oncologia Hospital de Câncer de Barretos, Rua Antenor Duarte Villela, 1331, Bairro Dr Paulo PrataCentro de Pesquisa Molecular em Oncologia Hospital de Câncer de BarretosDepartamento de Patologia Hospital de Câncer de BarretosPrograma de Pós-Graduação em Oncologia Departamento de Radiologia e Oncologia Faculdade de Medicina FMUSP Universidade de São Paulo FMUSPPrograma de Pós-Graduação em Ginecologia Obstetricia e Mastologia Faculdade de Medicina de Botucatu/UNESPPrograma de Pós-Graduação em Ginecologia Obstetricia e Mastologia Faculdade de Medicina de Botucatu/UNESPFAPESP: 2012/19642-0Hospital de Câncer de BarretosUniversidade de São Paulo (USP)Universidade Estadual Paulista (Unesp)Carrara, Guilherme Freire AngottiEvangelista, Adriane FeijoScapulatempo-Neto, CristovamAbrahão-Machado, Lucas FariaMorini, Mariana AndoziaKerr, Ligia MariaFolgueira, Maria Aparecida Azevedo Koikeda Costa Vieira, René Aloisio [UNESP]2021-06-25T10:33:37Z2021-06-25T10:33:37Z2021-03-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article307-320http://dx.doi.org/10.1007/s12282-020-01159-zBreast Cancer, v. 28, n. 2, p. 307-320, 2021.1880-42331340-6868http://hdl.handle.net/11449/20652510.1007/s12282-020-01159-z2-s2.0-85091143634Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengBreast Cancerinfo:eu-repo/semantics/openAccess2024-08-16T14:12:50Zoai:repositorio.unesp.br:11449/206525Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-16T14:12:50Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survival |
title |
Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survival |
spellingShingle |
Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survival Carrara, Guilherme Freire Angotti Biomarkers, tumor Breast neoplasms Neoadjuvant therapy Pathologic complete response Survival analysis |
title_short |
Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survival |
title_full |
Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survival |
title_fullStr |
Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survival |
title_full_unstemmed |
Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survival |
title_sort |
Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survival |
author |
Carrara, Guilherme Freire Angotti |
author_facet |
Carrara, Guilherme Freire Angotti Evangelista, Adriane Feijo Scapulatempo-Neto, Cristovam Abrahão-Machado, Lucas Faria Morini, Mariana Andozia Kerr, Ligia Maria Folgueira, Maria Aparecida Azevedo Koike da Costa Vieira, René Aloisio [UNESP] |
author_role |
author |
author2 |
Evangelista, Adriane Feijo Scapulatempo-Neto, Cristovam Abrahão-Machado, Lucas Faria Morini, Mariana Andozia Kerr, Ligia Maria Folgueira, Maria Aparecida Azevedo Koike da Costa Vieira, René Aloisio [UNESP] |
author2_role |
author author author author author author author |
dc.contributor.none.fl_str_mv |
Hospital de Câncer de Barretos Universidade de São Paulo (USP) Universidade Estadual Paulista (Unesp) |
dc.contributor.author.fl_str_mv |
Carrara, Guilherme Freire Angotti Evangelista, Adriane Feijo Scapulatempo-Neto, Cristovam Abrahão-Machado, Lucas Faria Morini, Mariana Andozia Kerr, Ligia Maria Folgueira, Maria Aparecida Azevedo Koike da Costa Vieira, René Aloisio [UNESP] |
dc.subject.por.fl_str_mv |
Biomarkers, tumor Breast neoplasms Neoadjuvant therapy Pathologic complete response Survival analysis |
topic |
Biomarkers, tumor Breast neoplasms Neoadjuvant therapy Pathologic complete response Survival analysis |
description |
Background: Non-metastatic locally advanced breast carcinoma (LABC) treatment involves neoadjuvant chemotherapy (NCT). We evaluated the association of clinical–pathological data and immunoexpression of hormone receptors, HER2 and Ki67, and new biomarkers, RPL37A, MTSS1 and HTRA1, with pathological complete response (PCR) or tumour resistance (stable disease or disease progression), disease-free survival (DFS) and cancer-specific survival (CSS). Methods: This is a retrospective study of 333 patients with LABC who underwent NCT. Expression of MTSS1, RPL37A and HTRA1/PRSS11 was evaluated by immunohistochemistry in TMA slides. Cutoff values were established for low and high tumour expression. ROC plotter evaluated response to NCT. Chi-square test for factors related to PCR, and Kaplan–Meier test and Cox model for factors related to DFS and CSS were prformed. Results: The mean follow-up was 70.0 months and PCR rate was 15.6%. At 120 months, DFS rate was 32.5% and CSS rate was 67.1%. In multivariate analysis, there was an association between: (1) necrosis presence, intense inflammatory infiltrate, ER absence, HER2 molecular subtype and high RPL3A expression with increased odds of PCR; (2) lymph node involvement (LNI), high Ki67, low RPL37A and high HTRA1 expression with increased risk for NCT non-response; (3) LNI, high proliferation, necrosis absence, low RPL37A and high HTRA1 expression with increased recurrence risk; (4) advanced LNI, ER negative tumours, high HTRA1, low RPL37A expression and desmoplasia presence with higher risk of cancer death. Conclusion: RPL37A is a potential biomarker for response to NCT and for prognosis. Additional studies evaluating HTRA1 and MTSS1 prognostic value are needed. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-06-25T10:33:37Z 2021-06-25T10:33:37Z 2021-03-01 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1007/s12282-020-01159-z Breast Cancer, v. 28, n. 2, p. 307-320, 2021. 1880-4233 1340-6868 http://hdl.handle.net/11449/206525 10.1007/s12282-020-01159-z 2-s2.0-85091143634 |
url |
http://dx.doi.org/10.1007/s12282-020-01159-z http://hdl.handle.net/11449/206525 |
identifier_str_mv |
Breast Cancer, v. 28, n. 2, p. 307-320, 2021. 1880-4233 1340-6868 10.1007/s12282-020-01159-z 2-s2.0-85091143634 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Breast Cancer |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
307-320 |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808128189630775296 |